Why Resilience Matters for Plasma-Derived Medicinal Products – PPTA Europe
PPTA Europe shared a post on LinkedIn:
”At today’s Friends of Europe panel on reimagining Europe’s health systems, the discussion focused on why health must be treated as strategic infrastructure for Europe’s economy, resilience and preparedness.
For plasma-derived medicinal products, resilience depends on recognising how these therapies are made – and getting the details right as the EU implements the general pharmaceutical legislation, the Critical Medicines Act and the Biotech Act.
PDMPs rely on healthy plasma donors, specialised infrastructure, complex supply chains, and manufacturing timelines that cannot be shortened overnight.
- One-size-fits-all solutions will not work for all critical medicines
- Health must be integrated into debates on preparedness, strategic autonomy and long-term investment
- Prevention, equity and practical implementation must guide how Europe plans for the future
Europe cannot reduce vulnerabilities in a single decision.
But realistic policy choices can help strengthen supply, support innovation and keep treatment available for the patients who depend on it.
Stay updated with Hemostasis Today.
-
Sep 11, 2026, 17:41Khaled Musallam: Earlier Recognition, Better Outcomes in NTDT
-
Sep 11, 2026, 17:29Reyhan Kose Cobanoglu: APS ACTION Registry Study Published in Lupus
-
Sep 11, 2026, 17:14Obi Light Ogbonnia: From Kenya to Global Sickle Cell Advocacy
-
Sep 11, 2026, 17:01EAHAD 2027 Marks 20 Years
-
Sep 11, 2026, 16:54Denise Braendgaard: Reimagining Health Systems Through Collective Action
-
Sep 11, 2026, 16:47Jehad Khamaysa: Budd-Chiari Syndrome as the Initial Presentation of Behçet’s Disease in a 16-Year-Old
-
Sep 11, 2026, 16:44Mostafa Faisal Mohammed Saleh: From HLA Biology to Curative Therapy
-
Sep 11, 2026, 16:38Jim Kaveney: Class I, Level A – Lifestyle is Now the Official Standard in AFib Care
-
Sep 11, 2026, 16:31George Touma: Do We Really Need to Implant Metal in Every High-Bleeding-Risk Patient?